CoChat

Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis

Open access

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Abstract

Aims: The purpose of this study is to investigate whether gene polymorphisms of the vascular endothelial growth factor A (VEGF-A) and its receptor (VEGFR-2) have a pharmacogenetics effect on the anti-VEGF treatment for neovascular age-related macular degeneration (nAMD). Methods: We carried out a meta-analysis focusing on the relationship between VEGF-related gene polymorphisms and treatment response of nAMD. Results: For the single nucleotide polymorphisms (SNPs) within VEGF-A and VEGFR-2 , anti-VEGF treatment was much more effective in patients with nAMD having rs833061 (CC vs TT:OR=2.222, 95% CI 1.252 to 3.944, p=0.006; CT vs TT: OR=2.537,95% CI 1.478 to 4.356, p=0.001 and CC vs CT+TT: OR=2.362, 95% CI 1.414 to 3.946, p=0.001), particularly for Asians (CC vs TT: OR=2.903, 95% CI 1.150 to 7.330, p=0.024; CT vs TT: OR=3.849, 95% CI 1.522 to 9.733, p=0.004 and CC vs CT+TT: OR=3.339, 95% CI 1.369 to 8.145, p=0.008, respectively). In subgroup analysis, rs833061 was more likely to be a predictor of response to anti-VEGF therapy specifically when ranibizumab (RBZ) only regime was adopted or visual acuity (VA) was taken as the standardised assessment of outcome. No association with response to anti-VEGF treatment was detected for the other eight polymorphisms. Conclusions: Pharmacogenetics of VEGF-A polymorphism rs833061 may play a positive role in response to anti-VEGF therapy for nAMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bjophthalmol-2016-309418

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow diagram of studies included in this meta-analysis.
Figure 1 Flow diagram of studies included in this meta-analysis.CC BY-NC · PubMed Central
Figure 2 The association between VEGF-A polymorphism rs833061 and treatment response of neovascular age-related macular degeneration (nAMD) based on the heterozygote model (CT vs TT). (A) Sub-analysis by ethnicity, (B) sub-analysis by treatment and (C) sub-analysis by definition of a good response (DGR).
Figure 2 The association between VEGF-A polymorphism rs833061 and treatment response of neovascular age-related macular degeneration (nAMD) based on the heterozygote model (CT vs TT). (A) Sub-analysis by ethnicity, (B) sub-analysis by treatment and (C) sub-analysis by definition of a good response (DGR).CC BY-NC · PubMed Central
Figure 3 Sensitivity analysis for rs699947 (A vs C) is shown.
Figure 3 Sensitivity analysis for rs699947 (A vs C) is shown.CC BY-NC · PubMed Central
Figure 4 Begg's funnel plot with pseudo 95% CIs for publication bias for rs833061 (CC vs TT) is shown.
Figure 4 Begg's funnel plot with pseudo 95% CIs for publication bias for rs833061 (CC vs TT) is shown.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 1

  1. 10.1101/cshperspect.a006502 · doi:10.1101/cshperspect.a006502 · Paper page

Cited by

See all 40

Metadata

Authors
Wu, M., Xiong, H., Xu, Y., Xiong, X., Zou, H., Zheng, M., Wang, X., & Zhou, X.
Affiliations
Second Affiliated Hospital of Chongqing Medical University (CN)
Corresponding author
Zhou, Xiyuan
Venue
British Journal of Ophthalmology
Publisher
BMJ
Published
2016-10-21
Volume
101
Issue
7
Pages
bjophthalmol-2016-309418
ISSN
  • 0007-1161 (ISSN-L)
  • 1468-2079
OpenAlex
W2535917791
Cited by
36
References
34
Citations by year
2026: 2 · 2025: 5 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 7 · 2018: 5 · 2017: 2
FWCI
0.91
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • British Journal of Ophthalmology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
National Natural Science Foundation of China (81401423, 81170858, 81501487)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
VEGF-A, VEGFR2, genetic polymorphism, neovascular age-related macular degeneration, anti-VEGF therapy, pharmacogenetics, treatment response, rs833061, ranibizumab, visual acuity, Asian patients
MeSH terms
Humans, Angiogenesis Inhibitors, Polymorphism, Single Nucleotide, Vascular Endothelial Growth Factor Receptor-2, Vascular Endothelial Growth Factor A, Wet Macular Degeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis. https://app.cochat.ai/papers/10.1136/bjophthalmol-2016-309418
The paper
Wu, M., Xiong, H., Xu, Y., Xiong, X., Zou, H., Zheng, M., Wang, X., & Zhou, X. (2017). Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2016-309418

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.